Stage Venture Partners is a seed venture capital firm that invests in emerging software technology for B2B markets. Founded in 2015 by two entrepreneurial partners, Stage is designed to deliver active, thoughtful investment and exceptional performance. One of us is a successful international operator who has built global businesses. The other is an experienced investor and venture capitalist with a strong track record. Stage VP invests in founders building cutting edge software technology for enterprise clients. Founders, especially those solving hard problems that matter, seek us out for our unique expertise, and our alignment with their daring vision. We have the conviction to be first; often the first institutional investor on the cap table and the first to identify new technological trends. We are not driven by thesis, geography, or sector. Instead, we seek out recurring revenue earned at the frontiers of what’s possible in enterprise software.  We believe we have the breadth to capitalize on investment opportunities across next-gen enterprise software, and the focus of a disciplined, expert investor.

Stage Venture Partners

Innospark Ventures is a new breed of early-stage venture capital firm, investing in the AI-driven economy.

Innospark Ventures

Wild Basin Investments, LLC is a closely held investment firm located in Austin, Texas with a strong portfolio emphasis in early stage equity.  Wild Basin was formed in November 2007 and is the most recent investment vehicle for a group of individuals who have participated in venture and angel investing since 1987.  Wild Basin usually co-invests with others in equity rounds; however, we will consider other investment structures including debt offerings. In addition to our early stage activity, Wild Basin provides portfolio management for pre-Wild Basin equity and real estate investments.  As a closely held private investment company, we do not accept outside funds and have broad discretion over how we deploy capital.

Wild Basin Investments

We invest in the dreamers, the thinkers, and the doers who have the ambition and persistence to change the world with their innovative tech. We will be your partner and champion throughout your journey.  Big Pi is a venture capital fund, investing in founders working on proprietary technologies that help solve big problems. We are excited by teams building solutions based on advances in computer science, artificial intelligence, life sciences and climate technologies. Some of our portfolio companies are already transforming their respective industries. We’ve been where you are at. Some of our team members have built very successful businesses  of their own (and failed multiple times as well). To really help you reach the promise land, it takes more than just investing money.   We have just launched our second fund and are ready to invest in the most exciting businesses of the future.

Big Pi Ventures

Motivate Venture Capital is a venture capital firm based in Chicago, IL. MVC invests in incredible founders with strong domain knowledge building new companies with very high growth potential in large and growing markets. Primary verticals of focus include Fintech, Insurtech, Payments, B2B software, B2B marketplaces, Crypto, DeFi, Blockchain, and web3.

Motivate Venture Capital

AI-first, seed-first fund in digital health, automation (cars, drones, robots) & enterprise. Tau Ventures was founded in 2019 and headquartered in Palo Alto, California.

Tau Ventures

An early-stage venture capital firm focused on identifying opportunities where technology will disrupt traditional, incumbent industries. It seeks founders with atypical backgrounds and out of the box thinking.

Outsiders Fund

Genesis Ventures is a coaching and angel investment platform for early-stage startups with a connection to Greece / South-East Europe. The firm was founded in 2021 and is based in Athens, Attiki, Greece.

Genesis Ventures

TLife Investments

HealthX Ventures is a digital healthcare-focused venture capital firm. They invest in innovative companies making healthcare safer, more efficient, and more affordable by delivering easy-to-use, cost-effective, and scalable solutions to the market.

HealthX Ventures

Cleveland Clinic Innovations (CCI) is the commercialization arm of Cleveland Clinic. CCI turns the breakthrough inventions of Cleveland Clinic employees into patient-benefiting medical products. The creation of new business opportunities allows CCI to deliver Cleveland Clinic’s unique capabilities into the commercial market, while aiding in the economic growth of Northeast Ohio and beyond. CCI facilitates an inclusive entrepreneurial environment where invention is fostered as an activity in which all can participate - physicians, nurses, researchers, administrators, etc. CCI’s comprehensive approach includes sophisticated deal teams, domain experts, investment funds, executives-in-residence, allied investors, seed and technology validation funds, incubation, preclinical and prototype facilities - all poised to create companies and commercially deploy new medical technology.

Cleveland Clinic Innovations

Tech Square Ventures is an Atlanta-based early-stage venture capital firm investing in enterprise, marketplace, platform, and tech-enabled service companies. We are a team of founders, operators, and investors that partner with visionary entrepreneurs to help them with what they need most – access to markets and customers. Our platform is built on a strategic network of innovation ecosystem and corporate, and university relationships that help founders inform and accelerate go-to-market strategies.

Tech Square Ventures

Dyania Health

Dyania Health is an NLP-based technology for pre-screening EMRs' unstructured and structured data to find patients who could be exact matches for clinical trials during a narrow window of time when their clinical characteristics match research protocol criteria. Our clients are pharma companies and healthcare systems.  The company was founded in 2019 and is based in Jersey City, NJ.

Dyania Health offers Synapsis AI, a platform that automates the reading and analysis of medical records to streamline clinical research and patient care. The company's proprietary large language model (LLM) can process both structured and unstructured medical data, including physician notes, pathology reports, and imaging notes within a healthcare system's firewall. The company claims Synapsis AI can analyze an electronic medical record in&nbsp;<a href="https://dyaniahealth.com/">0.5 seconds</a>, achieving over&nbsp;<a href="https://dyaniahealth.com/">94% accuracy</a>. The technology operates locally within healthcare systems' computing environments, ensuring compliance with the Health Insurance Portability and Accountability Act (HIPAA) and data security.&nbsp;

Discover Synapsis AI for Healthcare.

Dyania Health, Inc. raises $5.3M seed to advance their proprietary and physician-built natural language processing technology to drive better outcomes in clinical research.

Dyania Health raises $5.3M to help speed up clinical trials

Dyania Health Raises $5.3M in Seed Funding

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

Dyania Health secures $10M in Series A round led by HealthX Ventures

Dyania Health is a deep tech company that develops Synapsis AI, an artificial intelligence system designed to automate the manual review of patient medical histories. Founded in 2019, the company aims to address the time-consuming process of pre-screening patients for clinical trials. Dyania Health's proprietary technology de-identifies and derives clinically accurate meaning from unstructured and structured EMR-based patient data. The Synapsis AI system can read an Electronic Medical Record (EMR) in 0.5 seconds, significantly faster than the 30 minutes it typically takes a medically-trained professional. This speed allows for rapid pre-screening of patients for clinical trial enrollment and protocol optimization.
The company's technology operates behind healthcare system firewalls in a closed-off environment, ensuring patient data remains secure and compliant with regulations such as HIPAA, HITRUST, and GDPR. Dyania Health's AI system achieves over 94% accuracy when compared to a real medical professional. The platform is designed to be installed within a healthcare system's computing environment, either on-premise or in a private cloud. The company's in-house physician team plays a crucial role in training and fine-tuning the AI, assessing protocols, and ensuring the accuracy of Synapsis AI.
Dyania Health's mission is to enable physicians to focus on treating patients and ensure that patients have access to the best care and therapies at the exact moment they need them. The company's approach aims to accelerate clinical trials, bring drugs to market faster, improve patient outcomes, and potentially save lives by finding suitable candidates for clinical studies.
Key customers and partnerships
Dyania Health works with large health systems to create safe IT environments that unlock and de-identify unstructured patient data from electronic health record databases. John Chelico, Chief Medical Information Officer of Common Spirit and former Chief Information Officer of Northwell Health, has praised the company's approach, stating that it will be instrumental in accelerating the throughput of clinical trials accrual in a safe and compliant way. The company's technology is designed to serve various stakeholders in the healthcare industry, including patients, healthcare systems, physicians, and pharmaceutical sponsors, by streamlining the process of identifying suitable candidates for clinical trials and research studies.

Dyania Health offers Synapsis AI, a platform that automates the reading and analysis of medical records to streamline clinical research and patient care. The company's proprietary large language model (LLM) can process both structured and unstructured medical data, including physician notes, pathology reports, and imaging notes within a healthcare system's firewall. The company claims Synapsis AI can analyze an electronic medical record in&nbsp;<a href="https://dyaniahealth.com/">0.5 seconds</a>, achieving over&nbsp;<a href="https://dyaniahealth.com/">94% accuracy</a>. The technology operates locally within healthcare systems' computing environments, ensuring compliance with the Health Insurance Portability and Accountability Act (HIPAA) and data security.&nbsp;The platform enables enterprise-wide clinical trial pre-screening, automated chart review for observational studies, and automated registry reporting. Dyania Health's technology addresses the significant challenge of manual chart review in clinical trials, which the company notes can take&nbsp;<a href="https://markets.businessinsider.com/news/stocks/dyania-health-inc-raises-5-3m-seed-to-advance-their-proprietary-and-physician-built-natural-language-processing-technology-to-drive-better-outcomes-in-clinical-research-1031752018">18–24 months</a> to match patients with specific trial criteria. The platform can also automate complex registry reporting and quality control requirements for healthcare institutions, helping reduce manual workloads and administrative costs.Key customers and partnerships<a href="https://hitconsultant.net/2024/10/24/dyania-health-secures-10m-for-ai-powered-chart-review/">Cleveland Clinic emerged as an early adopter of Synapsis AI</a>, implementing the technology in its cancer and cardiovascular disease departments. Following successful results, Cleveland Clinic announced plans for an enterprise-wide deployment of the platform.

Headquartered in Amsterdam, Castor is a cloud-based e-clinical data platform that can be used for a range of tasks and processes during a clinical trial. It offers four solutions: 1) electronic data capture (EDC) to capture and process data from multiple sources including researchers, 2) electronic patient-reported outcomes (ePRO) to collect and manage patient-reported data on a centralized platform, 3) e-consent - to enable patients to be recruited, screened, and enrolled remotely, and 4) a decentralized clinical trials (DCT) platform to assist operators with managing DCT technologies and devices through a central platform. The company’s solutions are targeted at industries like biotech and pharma, diagnostics, and clinical research organizations. Its solutions are built in line with industry-standard compliance and data protection standards including HIPAA, GDPR, and ISO 27001.Castor aimed to collect enough clinical trial research data to enable the reuse of data for AI-driven clinical trials, which would lower the costs of operating clinical trials and reduce the time taken to bring new drugs to market.Key customers and partnershipsAs of June 2024, the company had supported 14,000+ studies and 6 million patients through clinical trials across 90+ countries, since launching in 2007. In terms of therapeutic areas, Castor had supported a range of different areas, including oncology, cardiovascular diseases, and diabetes. The company had been engaged by 500+ organizations, including the World Health Organization, Click Therapeutics, and Stryker. It was the first to incorporate machine learning into its system for the identification of Covid-19 patients. The company offered free access to its system for Covid-19 research projects, with over 200 projects using the platform as of June 2022. In February 2024, the company partnered with Microsoft to use Microsoft Azure to bring modern AI to clinical trials. The feature was released to help Castor users develop their studies faster by simplifying complex tasks in the study build process. The company additionally noted that it was planning to release its first in a line of Practical AI features to all its users in public Beta. Funding and financialsThe company raised USD 45 million in Series B funding in July 2021, led by Eight Roads Ventures and F-Prime Capital. The funds were earmarked for product development, interoperability with partner systems, and market research on decentralized trials. The company had a headcount of 150 at the time of the Series B and was planning to expand to 200 by the end of 2021.

Castor

Florence Healthcare offers a platform for clinical trial management. It has four key components: 1) SiteLink to start-up and monitor remote clinical sites, 2) eBinders to digitize and store research binders, 3) eConsent to simplify and digitize the consent process, and 4) Electronic Trial Master File to digitize the storage and transfer of files between sites and research sponsors. The platform is compliant with standard industry requirements including HIPAA, 21 C.F.R Part 11, ICF/GCP, and GDPR.Key customers and partnershipsAs of June 2024, Florence supported over 18,000 research sites, across 55+ countries, with key customers including Pfizer. The usage of the company’s software tripled in 2020, driven by an industry shift toward digitalization as a result of the Covid-19 pandemic. In February 2022, the company was ranked as the best clinical trial platform out of a group of 190 for ease of setup, ease of use, and customer support.Florence partnered with Greenphire, a company focusing on patient convenience and financial management for clinical trials, in Janauary 2024. Through the partnership, Florence's platform will be integrated with Greenphire's to improve payment systems within clinical trials. Benefits of the partnership included reduced manual work for sites, faster payments, and better visibility of site activity for sponsors and Contract Research Organizations (CROs). Funding and financialsThe company raised USD 80 million in Series C funding in May 2021 led by Insight Partners. The proceeds were to be used to scale up its sales and marketing teams and improve the value proposition of the platform by reducing the time required by customers to implement and manage clinical trials.

Florence Healthcare

Huma is a UK- and US-based clinical trial tech startup that provides a digital platform to manage clinical trials, including decentralized clinical trials. The platform can be used throughout the clinical trial process, including patient recruitment, screening, electronic consent, clinical outcome assessments, patient-reported outcomes, and telemedicine. The platform is built up to industry standards in data privacy and security, including ISO 27001, 21 C.F.R. Part 11, and TxP.In June 2023, the company <a href="https://sp-edge.com/updates/19352">received FDA 510(k) Class II FDA clearance </a>for its configurable disease-agnostic platform, including its cardiovascular risk score algorithm. The company received this FDA clearance in partnership with Health Canada and it allows Huma's platform to be used to monitor patients of all ages with any condition, including pediatrics and pregnancy. The Class II clearance also enables the platform to host algorithms that provide automated AI-driven data analytics for diagnosis, screening, clinical decision-making, predictions on health outcomes, and recommendations on dosage.In July 2024, the company was <a href="https://sp-edge.com/updates/31552">estimated to be valued at nearly USD 1 billion</a> when it secured a Series D investment of USD 80 million. Key customers and partnershipsSome of the key partners working with Huma include AstraZeneca, Johnson &amp; Johnson, Bayer, Stanford University, and the University of Cambridge. As of July 2024, the platform supported 3,000+ hospitals and clinics, screened over 35 million individuals, and had 1.8 million active users across 70 countries. Huma was awarded the 2021 Prix Galien Award, which is widely considered the “Nobel Prize” for pharmaceuticals and life sciences.The company announced a partnership with Xyla Elective Care in June 2022, to provide support to the UK’s National Health Service in delivering and managing virtual wards.

Huma

Based in California and founded in 2015, Medable is a digital clinical trial management platform with a range of modules for different processes. These modules include a decentralized clinical trial platform to support decentralized trials using remote tools for data gathering, monitoring, televisits, and consent; digital patient screening to screen patients remotely and at scale; e-consent to enable patients to digitally consent for clinical trials; electronic clinical outcome assessments; and patient-reported outcomes to document data in real time and provide easy access for researchers. It also includes remote patient monitoring to make it easy for patients to record and share data with clinical research teams.Medable operates on a SaaS business model, with customers having the option of selecting and deploying only the modules required as part of their uniquely customized solution.In <a href="https://sp-edge.com/updates/32647">August 2024</a>, Medable launched 'Medable Studio', an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisits, and sensors) into clinical trials. The no-code suite aimed to simplify the complex eCOA launch process, offering biopharmaceutical companies greater control and transparency. Medable Studio includesda point-and-click builder for creating assessments and instruments, a visual schedule of assessments builder, a translation workbench, and a content library. The platform enabled users to rapidly build and launch complex clinical trials, with the ability to create protocol-fit study designs in hours instead of months.In <a href="https://sp-edge.com/updates/35913">November 2024</a>, Medable launched Medable AI, a suite of GenAI capabilities integrated into its Studio platform. The suite aimed to streamline digital and decentralized clinical trials for sponsors and research organizations. The AI suite features automated eCOA creation that converts existing outcome assessments into a digital format, a ChatGPT-like interface for editing assessments, and scalable assessment-generation capabilities.&nbsp;As of <a href="https://hitconsultant.net/2024/10/30/medable-partners-with-google-cloud-to-accelerate-clinical-trials/">October 2024</a>, the company offered its platforms across 60 countries and was used across 300 decentralized and hybrid clinical trials. The company’s platform is compliant with industry standards, including HIPAA, FDA’s 21 CFR Part 11, and GDPR.Key customers and partnershipsAs of <a href="https://www.businesswire.com/news/home/20240607926468/en/Medable-Wins-2024-Prix-Galien-UK-Award-for-Best-Digital-Health-Solution">June 2024</a>, Medable claimed to work with 14 out of the top 20 pharmaceutical companies, in addition to working with a range of partners, including Cognizant, Accenture, Oracle, and PwC.In <a href="https://sp-edge.com/updates/35456">October 2024</a>, the company partnered with Google Cloud to offer its decentralized clinical trial platform on Google Cloud's marketplace. The collaboration combined Medable's clinical trial technology with Google Cloud's infrastructure and AI capabilities to streamline trial processes.In <a href="https://sp-edge.com/updates/29843">May 2024</a>, Medable partnered with Masimo, a medical technology provider, to incorporate new wearable devices in clinical research. Medable announced it would include the MightySat Rx pulse oximeter by Masimo in its platform for various major clinical trials, particularly in lung and breast cancer research.In <a href="https://sp-edge.com/updates/22394">October 2023</a>, the company partnered with Pluto Health, a healthcare coordination company, to enhance the clinical trial experience for participants and improve data collection during trials. Through the partnership, the companies aimed to connect patients to the right medical resources including access to clinical trials and home delivery of medication.&nbsp;In <a href="https://www.fiercebiotech.com/biotech/gsk-taps-medable-decentralized-clinical-trials-patient-diversity">September 2022</a>, the company announced a four year agreement with GlaxoSmithKline to use Medable’s platform for clinical trials across multiple products. Financial terms of the agreement were not disclosed.

Medable

Headquartered in New York, Obvio Health provides a full service for clients, supporting them throughout the clinical trial process from the design and recruitment stages to outcome measurement and reporting. In addition to its technological platform, the company provides professional services to execute clinical trials using its in-house clinical operations team. The platform caters to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, gi, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001.According to the company, its platform was designed from the ground up to cater to digital trials run by virtual clinical teams, which resulted in faster patient recruitment (three months for Obvio compared to 12 months for physical site trials). In January 2022, the company launched an augmented electronic patient-reported outcome (augmented ePRO) module, which incorporates AI and manual scoring by experts/clinicians. The company claims this improves the accuracy and quality of data collected.In April 2024, the ObvioHealth launched ObvioGo 2.0, an enhanced platform and mobile application designed to meet the unique needs of trial sites and sponsors. The upgraded platform allows the combination of hybrid and virtual trial designs within one study. It includes features such as the ability to create site-specific workflows, integration with other clinical systems, and a streamlined translation process. Additional features include a built-in virtual assistance team, COACH, for trial tasks support and a patient identifier tool for patient registration and data correlation.As of June 2024, the platform catered to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, GI, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001. Key customers and partnershipsAs of June 2024, Obvio Health’s client base included companies like GlaxoSmithKline, Pfizer, Bayer, Danone, and General Mills. As of June 2024, the company’s operations were spread over 28 countries and had supported obtaining consent from 40,000+ patients across 40 clinical trials since its launch.In March 2022, Obvio partnered with Renovia to conduct the first fully virtual trial in urogynaecology, based on Renovia’s Leva device. The device helped patients with performing kegel exercises more effectively, in addition to monitoring compliance over the trial period.In November 2023, Obvio then partnered with Chemist Warehouse, the largest retail pharmacy chain in Australia, to improve the reach and efficiency of clinical trials. Through the partnership, Chemist Warehouse agreed to promote ObvioHealth-managed trials to its customers in Australia, using both offline and online channels. Additionally, ObvioHealth agreed to utilize Chemist Warehouse's Telehealth services for studies that require clinician assessments. The collaboration aimed to increase the awareness and convenience of clinical trials, addressing two major hurdles in participant recruitment. The long-term goal of the partnership was to expedite the introduction of innovative therapies to the market more efficiently and economically. Funding and financialsThe company raised USD 31 million of Series B funding in June 2021 led by Dedalus Group and Novotech Health. The investment was primarily strategic, with Obvio benefiting from its Dedalus partnership in terms of European clinical trial compliance, while it became Novotech Health’s preferred virtual clinical trial provider.

Obvio Health

Companies offering data and workflow management platforms and solutions to assist with the operational management of a clinical trial, including site management, monitoring processes in terms of risk and documentation, and payment automation.

Companies using remote patient monitoring tools and other connectivity solutions to enable remote collection of patient data and monitoring and run trials virtually, without requiring the patient to be physically present in the clinical trial site.

Companies that offer workflow management platforms that are used to manage logistics tasks and processes for clinical trials, primarily the randomization of assigning patients in a clinical trial and automation of logistics workflows based on clinical trial data.

This is the use of software, incorporating AI and Machine Learning technology to improve the matching process of patients with suitable clinical trials.

Companies that offer software solutions for identifying and evaluating potential trial sites, along with documentation and workflow management systems to complete the processes before launching, including electronic patient consent and other required regulatory tasks.

Includes companies that provide digital data management platforms to collect and store patient reported outcome data. These platforms are also incorporating data analytics to help understand the results and identify trends and patterns. Additionally, the platforms are enabling connectivity with remote monitoring devices, including Medical Internet of Things.

Companies that provide software tools that help with the design of clinical trials, including identifying protocol violations, collecting participant input on potential design ideas for the trial, and crowdsourcing of protocol ideas for clinical trials.

Companies that use GenAI as a core part of their product offering for Clinical Trial Tech

Startups in this hub use IoT to support report patient monitoring and data gathering

AI/ML algorithms can be used to automate the analysis of patient data

Offers digital platforms that accelerate clinical trials and evaluations

Most CTT platforms are offered on a B2B basis to companies carrying out clinical trials

Startups in this hub seek to improve clinical trial diversity by including underrepresented communities

Clinical Trial Technology providers incorporate GenAI to enhance their platform’s capabilities and utility

<div>
 
 Dyania Health, an AI based healthcare data firm, managed to gather USD 10M in Series A funding with leading support from HealthX Ventures. Other participants included Tech Square Ventures, Cleveland Clinic Ventures along with the previous investors. This inflow of funds has brought the company's total fund pool to a whopping figure of USD 15.3M.
 These funds are earmarked for various growth initiatives, including the expansion of AI capabilities within the company. Additionally, they will further develop their own Synapsis AI platform and upscale the operational bandwidth, satisfying the burgeoning demand from healthcare institutions and biopharmaceutical companies. 
 Dyania's Synapsis AI platform works by processing both unstructured and structured healthcare data, within the firewalls of the healthcare systems. The platform does all this while maintaining supreme compliance with HIPAA and GDPR. By performing complex medical chart reviews in under a second, the platform helps healthcare and life science organizations extract valuable insights from unstructured clinical data. It's interesting to note that Cleveland Clinic was among the early adopters of this platform.
 
</div>

Dyania Health

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless